olaparib ATM Loss, +27 more biomarkers Prostate Carcinoma Castration-resistant, +1 more state Subsequent line olaparib targeted therapy
cisplatin + gemcitabine BRCA1 Loss, +5 more biomarkers Pancreatic Adenocarcinoma Locally advanced, +1 more state First line cisplatin, +1 more drug chemotherapy
cisplatin + gemcitabine BRCA1 Loss, +5 more biomarkers Pancreatic Adenocarcinoma Locally advanced, +2 more states Subsequent line cisplatin, +1 more drug chemotherapy
cisplatin + gemcitabine +/- chemoradiotherapy BRCA1 Loss, +5 more biomarkers Pancreatic Adenocarcinoma Primary Neoadjuvant chemoradiotherapy, +2 more drugs chemotherapy, +1 more type
olaparib ATM Loss, +27 more biomarkers Prostate Adenocarcinoma Castration-resistant, +1 more state Subsequent line olaparib targeted therapy
rucaparib BRCA1 Loss, +5 more biomarkers Pancreatic Adenocarcinoma Metastatic Maintenance rucaparib targeted therapy
pidnarulex ATM Loss, +27 more biomarkers Breast Carcinoma, +1 more condition pidnarulex targeted therapy
Cancer Search
